Literature DB >> 28939133

Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?

Velia Chiara Di Maio1, Valeria Cento1, Marianna Aragri1, Stefania Paolucci2, Teresa Pollicino3, Nicola Coppola4, Bianca Bruzzone5, Valeria Ghisetti6, Maurizio Zazzi7, Maurizia Brunetto8, Ada Bertoli1, Silvia Barbaliscia1, Silvia Galli9, William Gennari10, Fausto Baldanti2, Giovanni Raimondo3, Carlo Federico Perno1, Francesca Ceccherini-Silberstein11.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28939133     DOI： 10.1016/j.jhep.2017.09.008

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  10 in total

1.  Emergence and Persistence of Resistance-Associated Substitutions in HCV GT3 Patients Failing Direct-Acting Antivirals.

Authors:  Saima Mushtaq; Asraf Hussain Hashmi; Amjad Khan; Syed Muhammad Asad Raza Kazmi; Sobia Manzoor
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.988

2.  Cell Culture Studies of the Efficacy and Barrier to Resistance of Sofosbuvir-Velpatasvir and Glecaprevir-Pibrentasvir against Hepatitis C Virus Genotypes 2a, 2b, and 2c.

Authors:  Santseharay Ramirez; Carlota Fernandez-Antunez; Lotte S Mikkelsen; Jannie Pedersen; Yi-Ping Li; Jens Bukh
Journal:  Antimicrob Agents Chemother       Date:  2020-02-21       Impact factor: 5.191

3.  NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients.

Authors:  Maria Concetta Bellocchi; Marianna Aragri; Luca Carioti; Lavinia Fabeni; Rosaria Maria Pipitone; Giuseppina Brancaccio; Maria Chiara Sorbo; Silvia Barbaliscia; Velia Chiara Di Maio; Fabrizio Bronte; Stefania Grimaudo; Walter Mazzucco; Ferdinando Frigeri; Marco Cantone; Antonio Pinto; Carlo Federico Perno; Antonio Craxì; Giovanni Battista Gaeta; Vito Di Marco; Francesca Ceccherini-Silberstein
Journal:  Cells       Date:  2019-07-02       Impact factor: 6.600

4.  Hepatitis C virus enhances Rubicon expression, leading to autophagy inhibition and intracellular innate immune activation.

Authors:  Yuto Shiode; Hayato Hikita; Satoshi Tanaka; Kumiko Shirai; Akira Doi; Sadatsugu Sakane; Yugo Kai; Tasuku Nakabori; Ryoko Yamada; Takahiro Kodama; Ryohei Narumi; Ryotaro Sakamori; Hidetoshi Eguchi; Takeshi Tomonaga; Tomohide Tatsumi; Tetsuo Takehara
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

5.  Resistance-associated substitutions and response to treatment in a chronic hepatitis C virus infected-patient: an unusual virological response case report.

Authors:  Fabián Aldunate; Natalia Echeverría; Daniela Chiodi; Pablo López; Adriana Sánchez-Cicerón; Martín Soñora; Juan Cristina; Gonzalo Moratorio; Nelia Hernández; Pilar Moreno
Journal:  BMC Infect Dis       Date:  2021-04-26       Impact factor: 3.090

6.  HCV-positive kidney transplant patients treated with direct-acting antivirals maintain stable medium-term graft function despite persistent reduction in tacrolimus trough levels.

Authors:  Maria Rendina; Ernesto Paoletti; Nunzia Labarile; Antonella Marra; Andrea Iannone; Antonino Castellaneta; Elisabetta Bussalino; Maura Ravera; Antonio Schena; Nicola M Castellaneta; Michele Barone; Simona Simone; Loreto Gesualdo; Alfredo Di Leo
Journal:  Ther Adv Chronic Dis       Date:  2022-09-17       Impact factor: 4.970

Review 7.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

8.  Prevalence of Single and Multiple Natural NS3, NS5A and NS5B Resistance-Associated Substitutions in Hepatitis C Virus Genotypes 1-4 in Italy.

Authors:  Ada Bertoli; Maria Chiara Sorbo; Marianna Aragri; Ilaria Lenci; Elisabetta Teti; Ennio Polilli; Velia Chiara Di Maio; Laura Gianserra; Elisa Biliotti; Chiara Masetti; Carlo F Magni; Sergio Babudieri; Laura A Nicolini; Martina Milana; Pierluigi Cacciatore; Loredana Sarmati; Adriano Pellicelli; Stefania Paolucci; Antonio Craxì; Filomena Morisco; Valeria Pace Palitti; Massimo Siciliano; Nicola Coppola; Nerio Iapadre; Massimo Puoti; Giuliano Rizzardini; Gloria Taliani; Caterina Pasquazzi; Massimo Andreoni; Giustino Parruti; Mario Angelico; Carlo Federico Perno; Valeria Cento; Francesca Ceccherini-Silberstein
Journal:  Sci Rep       Date:  2018-06-12       Impact factor: 4.379

9.  Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion.

Authors:  Christopher D Ma; Michio Imamura; Daniel C Talley; Adam Rolt; Xin Xu; Amy Q Wang; Derek Le; Takuro Uchida; Mitsutaka Osawa; Yuji Teraoka; Kelin Li; Xin Hu; Seung Bum Park; Nishanth Chalasani; Parker H Irvin; Andres E Dulcey; Noel Southall; Juan J Marugan; Zongyi Hu; Kazuaki Chayama; Kevin J Frankowski; Tsanyang Jake Liang
Journal:  Nat Microbiol       Date:  2020-08-31       Impact factor: 17.745

Review 10.  The Role of RASs /RVs in the Current Management of HCV.

Authors:  Konstantinos Malandris; Georgios Kalopitas; Eleni Theocharidou; Georgios Germanidis
Journal:  Viruses       Date:  2021-10-18       Impact factor: 5.048
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.